Hoyoung Huh



Chairman & CEO

pH Group Companies

Serial healthcare  founder, entrepreneur & investor driven by innovative science, creative collaborations and impact investing. Involved in formation, management and growth of healthcare companies in cancer therapies (BiPar, Geron, CytomX, Facet, Jennerex, EOS), diabetes/metabolism (Rezolute, Pliant, Calibra, Nektar), breakthrough science (Eidos, BridgeBio, 4DMT) and technology-enabled impact companies (Shared-X, G2G). Former Board Member of SF Jazz, Berklee School of Music, ReSurge International; current Board Member of Dartmouth Medical School.

Steve Ferguson



Deputy Director, Licensing & Entrepreneurship, Office of Technology Transfer

National Institutes of Health (NIH), , 

Chair, Department of Technology Transfer, Foundation for Advanced Education in the Sciences (FAES) Graduate School,

Bethesda, Maryland, USA

Steven M. Ferguson currently serves as the Deputy Director, Licensing and Entrepreneurship. Prior to joining NIH Office of Technology Transfer in 1990, Mr. Ferguson served in marketing and management positions in biomedical firms subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital. Registered to practice before the USPTO and a Certified Licensing Professional (CLP), 

Dmitry Vinarov





Dmitriy A. Vinarov, Ph.D., M.B.A. is an Equity Partner with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Vinarov has a broad range of experience in intellectual property law, including patents, trademarks, unfair competition, copyrights, and trade secrets. Dr. Vinarov’s practice at MBHB encompasses primarily all phases of U.S. and foreign patent prosecution, with an emphasis on pharmaceuticals, biological, diagnostics, biochemistry, cell biology, immunology, molecular biology, medical devices, and diagnostics. Dr. Vinarov also provides client counseling in the areas of patentability, freedom-to-operate, infringement, and validity analyses. Dr. Vinarov’s client list includes Fortune 100 companies, mid-size companies, startups, and academic institutions.

Muhammad Tani bin Tabiin



General Manager

Temasek Life Sciences Accelerator and Vertex Ventures 

Chief Business Officer at miRNA diagnostics company, MiRXES Pte Ltd since July 2015 and Chief Strategy Officer from Oct 2017. In charge of Business Development, Collaborations, Fund Raising and Intellectual Property Management for the NUS/A*STAR spin-off.
Before joining MiRXES, Dr Tabiin worked his way up from Assistant Manager to Senior Vice President and the Head of the Biomedical Sciences Division, ETPL, the Strategic Marketing and Commercialisation arm of A*STAR (Agency for Science, Technology and Research, Singapore) during his 10+ years there with extensive licensing and spin-off  experience. Prior to that he had an extensive career in industry.

Tony Jones


CEO, One Nucleus


•After completing a PhD in Biochemistry (1992) from the University of Southampton UK, Tony Jones undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund taking novel neuropeptide antagonists into Phase 1.

•In 1997, he moved into Technology Transfer with the Medical Research Council and moved to University College London, where he was business development manager at the Wolfson Institute for Biomedical Research until November 2003. He then took up the post of director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery, moving the LBN from a primarily inward looking London group to an outward facing business network. In May 2010 Tony took London Biotechnology Network into the merger with ERBI (now One Nucleus) seeing this as the best manner in which to continue assisting their respective member companies in developing their businesses.

Vibhu Sachdev


Assistant Director, Business Development and Licensing

Office of Technology Transfer

The Rockefeller University , NY

•Previously, Senior Technology Licensing Officer, Weill Cornell Medical College, New York, NY, USA

•Highly experience technology transfer licensing officer

•Specialized in devices, diagnostics, digital health, big data, health records, analytics

•Proven deal maker

•Previosuly at MIT Technology Licensing Office

•JD, qualified patent attorney (Foley & Larder LLP)

Raúl Martin-Ruiz


Principal, Ysios Capital, Madrid, Spain

Raúl coordinates the identification and evaluation of investment opportunities from the scientific and business perspectives. He also directs the preparation of the scientific and business reporting to the Investment Committee and collaborates in the monitoring of Ysios’s portfolio companies.

Raúl serves on the board of MedLumics, Anaconda Biomed and Corwave. Formerly he was board member at Prexton Therapeutics, acquired by Lundbeck, and STAT-Dx, acquired by Qiagen.

Prior to joining Ysios in 2008, Raúl worked at Almirall where he was responsible for managing and developing the company’s business through licensees and distributors in America and Africa. Before that, he worked in Almirall’s corporate business development department, focusing on in- and out-licensing. At Almirall he interacted with numerous pharmaceutical and biotech companies on a global basis and coordinated and led evaluation and approval several licensing projects in different therapeutic areas, from the technical, commercial, contractual, financial and business perspectives.

Raúl began his career in research. He worked on central nervous system pharmacology in the department of pharmacology of the University of the Basque Country (UPV/EHU), and on neurochemistry in the department of neurochemistry of the Institute for Biomedical Research of Barcelona (IIBB)- Spanish National Research Council (CSIC).

Raúl holds a bachelor’s of science in biological sciences from UPV/EHU and a PhD in neurosciences from UPV/EHU and CSIC.

Luis Campo


GE Healthcare Country Manager Spain & Southern Europe Services GM

Anton Pekcec


Research Beyond Borders, Boehringer Ingelheim Pharma, Germany 

Analia Lemmo Charnalia


Senior Business Manager, UCL Business, University College London, UK 

Almudena Trigo


President & General Partner, BeAble Capital, Madrid, Spain

Asunción Gomez


Vicerrectora Investigación, Transferencia y Doctorado. Universidad Politécnica de Madrid

Phil Jackson


 Projects Director, MedCity, London, UK  

Isabel Lozano


CEO Atrys Health , Madrid, Spain

Claus Schulte


Ascenion GmbH, Munich, Germany

Martín Rivas Anton


Director General, UNINVEST, Madrid, Spain

Markus Goebel

CEO M&G Advisors, Zürich, Switzerland


• Managing Director Novartis Venture Fund in the US&EU since 2004, having served as a director of several private companies in Bio- and Medtech

• In the Health Care Industry since 1990; extensive US&EU hands-on experience

- Focus areas: Product and company assessment, valuation, deal structures, and financials

- Several deals successfully concluded in VC, BD&L and M&A

• MBA finished with dissertation on innovation in the Pharma industry to characterize blockbuster drugs

• Certified MD in Oncology/Haematology (plus additional certifications) with >10 years academia

Oliver Chao


Head, Emerging Biomedical Sciences, Sanofi External Innovation,Sanofi, Paris, France 

Dr. Chao has over 20 years of pharma experience, working closely with both industrial and academic partners.  He has extensive and in depth knowledge from traditional drug discovery/therapeutic strategy to emerging sciences and exploratory biotechnology.

Miguel Holgado


Bachelor's and Master's degree in Electrical Engineering from Technical University of Madrid (UPM) (1996), and Deputy Vice-Rector for Innovation, group leader of the Optics, Photonics and Biophotonics at the Center for Biomedical Technology CTB-UPM, and professor at the Applied Physics and Material Engineering Department of Industrial Engineering School (ETSII-UPM). 

Professional Experience as an R&D engineer at Laser Section at the Spanish Ministry of Defense and responsible for RAMAN spectroscopy service Lab at ICMM-CSIC. Process engineer at Lucent Technologies Microelectronics during 4 years, Spanish representative in the 5th and 6th European R&D Framework Programme at the Center for Industrial Technology (CDTI), Sub-director of RTD projects at Nanophotonics Technology Center at Technical University of Valencia and Head of European Communities Unit at CSIC

Founder of Bio Optical Detection; a spin-off company (BIOD S.L.) which develops optical Point-of Care devices and offers IVD screening services Doctoral degree (Ph.D.) at the Institute of Material Science (ICMM) belonging to the Spanish National Research Council CSIC (2000). 

Vince Smeraglia


Executive Director, Office of Research Commercialization, Rutgers University, NJ, USA 

Executive Director of Strategic Alliances, developing biomedical Rutgers collaborative relationships with universities, foundations and corporate partners. Previously, he was the Executive Director of the Rutgers Office of Technology Commercialization, overseeing patenting and licensing of Rutgers inventions. He was also the Executive Director of the UMDNJ Office of Technology Transfer & Business Development before UMDNJ and Rutgers merged. Before joining UMDNJ/Rutgers, Vince conducted biomedical research at CytogenCorporation, developing antibody conjugates for diagnostic and therapeutic clinical uses. Vince has a B.S. in Biochemistry from Rutgers, and a Masters of Intellectual Property and J.D. from the University of New Hampshire Law School.

Morris Berrie


Co-Founder & Chairman

Tech Transfer Summit Ltd.

London, UK

Morris advises companies on “the business of science”, i.e. business development, strategy, licensing and capital raising. 

Previously he was both the Chief Executive Officer and Editor-in-Chief of the Biotechnology Investment Group. Prior to that he was Head of Global Intelligence and Business Development for Nature Publishing Group and responsible for the research and development of key product launches and the organization of the Business Intelligence Seminars. 

Dr. Berrie began his career at Current Drugs (now Thomson Reuters) where he was Director of the life science patent and drug registry content of the Investigational Drug database (IDdb). He has worked at: Schering AG, GlaxoWellcome, is a Chartered Chemist (CChem), a Member of the Royal Society of Chemistry (MRSC) and was the recipient of a European DG Post-Doctoral Fellowship upon completing his Ph.D. at Imperial College, London. He also sits on the Business Strategy, Publishing and Awards Committees of the Royal Society of Chemical Industry.

Lorena Muñoz



Fundadora y Socia Directora, Effectia Innovation Solutions

Cuenta con más de 19 años de experiencia profesional en consultoría estratégica en innovación: 

Anteriormente fue directora de sector público en SILO - Science & Innovation Link Office, gerente de Sector Público – Innovación de Deloitte S.L., gerente de Sector Público – Innovación de Everis S.L. y consultora senior en Vitalia Consulting, donde ha trabajado en estrategia, diseño y transformación de organizaciones, y en particular en el diseño, puesta en marcha y evaluación de políticas públicas para promover la ciencia, tecnología, innovación, formación universitaria, creación de empresas de base tecnológica, etc. Formó parte de los comités de innovación tanto de Deloitte como de Everis, asumiendo el rol de Innovation Manager y promoviendo la implantación de los modelos de gestión de la innovación en ambas compañías. 

Inició su carrera profesional en investigación básica en drug discovery en el departamento de microbiología del Centro de Investigación Básica de España (CIBE) de MSD.

Christian J. Suojanen


Co-Founder & Chairman, Global Initiative.

Strategic Advisor. USA

20 years strategic advisory and operational experience in the biotech, pharma and innovation sectors. An advisor to biotech CEOs on fund raising, business development and strategy, to industry on innovation, pipeline and business development, to institutions on technology transfer & innovation, to venture capital on models and capital formation, with associations and trade groups (biotech, pharma, venture capital, patients), and governments on innovation strategy, policy, and ecosystem development., he is also co-founder/chairman of the leading international platform connecting biotech and health tech transfer officials with top industry executives, investors, entrepreneurs, IP and other innovation and start-up experts.

He led a turn-around of Europe’s largest biotech association, was the lead advisor, dialogue moderator and “rapporteur” for the European Commission’s 3 year strategic “Innovation in Healthcare” initiative to revise innovation funding policy based on stakeholder input from industry executives, VCs, biotech CEOs, and technology transfer directors, and has worked with SMEs, industry and governments in Europe, North America and Latin America. 

He coordinated the first European level entrepreneur training bootcamp for biotech founders/CEOs, built the first European biotech investment initiative in collaboration with the European Commission and EASDAQ (now Euronext), industry and investors, and has extensive experience coaching & mentoring entrepreneurs, CEOs and tech transfer directors. 

Christian has deep cross functional sector expertise and an exceptional international network of key innovation stakeholders from industry, finance, SMEs & research.